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SummarY Dysesthetic pain following traumatic myelopathy is characterized by diffuse burning and 
tingling sensations distal to the level of spinal injury. The dysesthetic pain syndrome (DPS) can 
compromise performance of functional abilities and inhibit participation in rehabilitation programs. 
Recent laboratory evidence suggests that antidepressant medications with selective inhibition of serotonin 
reuptake in the brain may be associated with superior analgesic effect compared to such non-selective 
agents as amitriptyline. Trazodone hydrochloride is a potent presynaptic serotonin reuptake blocker with 
few anticholinergic and cardiovascular side effects. This study was a randomized, double-blind, placebo- 
controlled trial of trazodone hydrochloride for the treatment of DPS. Following a 2-week placebo lead-in 
period, patients were randomized to a 6-week course of 150 mg trazodone hydrochloride/day or placebo. 
Evaluations of pain quality and intensity were performed at 2-week intervals, utilizing the McGill Pain 
Questionnaire, Stembach Pam Intensity Scale, and Zung Pam and Distress Index. Neurologic examina- 
tion and assessment of side effects were performed at each evaluation session. No significant changes 
were noted in reported pain measures between patients allocated to the active drug group and those given 
placebo during the course of the protocol. However, significantly more patients randomized to trazodone 
complained of side effects and prematurely terminated their participation in the study. The results of this 
investigation are consistent with those of other earlier trials which indicate that such antidepressant 
medications as trazodone hydrochloride which selectively inhibit presynaptic reuptake of serotonin, may 
not be effective in the control of certain pain syndromes. These results do not preclude the possible 
utility of these agents in the treatment of other pain syndromes or at higher doses than previously 
studied. 
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Introduction 
Pain is a frequent complication of traumatic myelopathy [5,30] and was exten- 
sively reviewed by Burke [8] and Donovan et al. [II]. Pain syndromes following SC1 
have been classified into 5 major groups: myofascial pain at or above the level of 
spinal injury, psychogenic pain, visceral pain, radicular pain and diffuse dysesthetic 
pain distal to the level of injury [ll]. 
Reported treatments of pain following SC1 have included transcutaneous nerve 
stimulation [4]. epidural electrical stimulation [34]. cordectomy [28], rhizotomy [12], 
ablation of the dorsal root entry zone [29,36] and psychotropic medications [18,25]. 
Studies designed to evaluate the efficacy of these interventions have been limited by 
two fundamental methodologic flaws: these studies failed to precisely identify the 
types of pain syndromes under treatment and these protocols generally did not use 
reliable established measures of pain quality and intensity. 
There have been many reports of the therapeutic efficacy of tricyclic antide- 
pressant (TCAD) medications in the treatment of pain syndromes [9,22,39]. Two 
reports suggested TCAD medications were effective in the treatment of radicular 
and dysesthetic pain following traumatic myelopathy [l&25]. Most studies testing 
the efficacy of TCAD medications in the treatment of pain have used amitriptyline, 
which interferes with the reuptake of serotonin and norepinephrine in a 1 : 2.8 ratio 
[35]. The work of Akil, Mayer, Liebeskind and associates [ 1,24,26] has provided data 
to support the use of TCAD medications in the treatment of pain syndromes. They 
reported that analgesia induced by electrical stimulation of the nucleus raphe 
magnus in rats was enhanced by administration of 5-hydroxytryptamine (serotonin) 
and reduced by norepinephrine administration. An agent with more selective 
inhibition of presynaptic serotonin reuptake than amitriptyline would thus be 
expected to provide superior analgesia, but 3 previous reports failed to demonstrate 
efficacy of serotonin reuptake blockers in the treatment of chronic pain syndromes 
[3,14,20]. 
Trazodone hydrochloride is a new antidepressant medication which selectively 
inhibits serotonin and norepinephrine reuptake in a ratio of 25 : 1 [35]. It was 
anticipated that this high specificity for serotonin might promote analgesia in a 
select group of patients with a well-defined pain syndrome. The present study was a 
randomized, double-blind, placebo-controlled trial to test the efficacy of trazodone 




The study group consisted of inpatients and outpatients at the Rehabilitation 
Institute of Chicago (RIC), Northwestern University Medical School, Chicago, IL 
who developed dysesthetic pain following traumatic myelopathy. Patients were 
referred to one of the physician-investigators (E.R.), who performed an initial 
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screening evaluation of each subject. Patients who met study criteria were invited to 
participate in the study. 
Patients were excluded if they were under 18 years of age, lacked English fluency 
or had a history of recent ethanol or substance abuse. All patients met the following 
criteria: 
(a) A history of dysesthetic pain of at least 1 month duration, and initial onset 
within the first post-injury year; 
(b) Failure to respond to conventional treatment, including therapeutic exercise, 
physical modalities, non-prescription analgesics, non-steroidal anti-in~ammato~ 
agents or narcotics; and 
(c) Pain-induced functional impairment, defined as the presence of one or more 
of the following: (1) disturbance of sleep-wake cycle; (2) inability to perform 
self-care activities; or (3) inability to fully comply with a therapeutic exercise 
program. 
A thorou~ review of potential risks and benefits of participation was performed 
by one of the physician-investigators. All patients gave informed written consent. 
This study was approved by the Institutional Review Board, Northwestern Univer- 
sity Medical School, Chicago, IL, and by the Food and Drug Ad~~stration, 
Washington, DC. 
Procedure 
This investigation consisted of a randomized, double-blind, placebo-controlled 
trial of trazodone hydrochloride in the treatment of patients with dysesthetic pain 
secondary to traumatic myelopathy. At the time of enrollment, general medical 
history and review of systems were elicited and physical and neurological examina- 
tions were performed. Determinations of motor and sensory levels and degree of 
completeness of injury were made according to the American Spinal Injury Associa- 
tion criteria [2]. A complete blood count with differential, urinalysis and chemistry 
profile was obtained at enrollment and termination from the study protocol. After 
the initial evaluation, patients were given, in a single-blind fashion, 1 placebo 
capsule/day for 2 weeks. Following this placebo lead-in period, patients were 
prescribed, in a double-blind fashion, 1 capsule/day of randomized medication for 
3 days, 2 capsules/day for the next 4 days, and 3 capsules/day for the remaining 5 
weeks of the study. Patients were evaluated in the clinic by a physician-investigator 
every 2 weeks until the patient completed the S-week protocol or terminated 
participation in the study. Adverse reactions, orthostatic blood pressure measure- 
ment, heart rate and neurologic examination results were recorded at each follow-up 
clinic visit. Compliance was determined by review of patient drug diaries and pill 
counts at each evaluation session. At the completion of the g-week protocol, 
patients were offered the opportunity to continue the use of the same medication in 
double-blinded fashion. These patients were re-evaluated at monthly intervals until 
they discontinued participation in the study. At termination, physicians and patients 
completed subjective global assessments of medication efficacy. 
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The following instruments for pain assessment were administered at the time 01 
enrollment and every 2 weeks until termination of each patient’s participation in the 
study protocol. 
McGill Pain Questionnaire (MPQ) (271 
The MPQ generated information concerning affective, sensory and evaluative 
aspects of pain [27]. Three types of measures were obtained from the MPQ: The 
pain rating index (PRI) was based on the rank value of pain descriptors chosen 
from a 20-category word list. A trained research assistant administered the MPQ to 
each patient, who selected the word in each category that best described his or her 
pain at the time of evaluation. The number of words chosen (NWC) from the same 
20-item inventory also was recorded. The present pain intensity (PPI) indicated the 
magnitude of pain on a 5-point scale. Previous authors have reported the MPQ to be 
a valid, reliable and reproducible instrument for pain assessment [ 15.23.27.31,32]. 
Sternbach Pain Intensity (SPI) (37j 
The patient was asked to rate his or her pain intensity on a scale of lLlO0, in 
which a score of zero represented no pain, and a score of 100 was equivalent to pain 
so severe that the patient would commit suicide. SPI ratings were obtained for the 
day of assessment (SPI-day) and for the week prior to clinic visit (SPI-week). 
Sternbach demonstrated that the scale was valid for assessing neurogenic and 
myofascial pain syndromes [37]. 
Zung Pain and Distress Index (PAD) (40~’ 
Each patient responded by indicating the extent to which he or she agreed with 
statements describing mood and behavioral changes associated with pain. This 
self-administered 20-item questionnaire has been shown to be a valid and reliable 
index of pain and accompanying emotional distress [40]. 
Data analysis 
Frequency distributions for sex, neurologic level, completeness of spinal lesion, 
surgical stabilization and etiology of injury were generated for drug and placebo 
groups. Significant differences in these frequencies were determined using the 
normal approximation of the binomial distribution to obtain confidence intervals. 
Student’s t test was employed to compare age, duration of pain symptoms and 
baseline pain measures between drug and placebo groups. 
A repeated measures analysis of variance and covariance [lo] was performed on 
the pain variables derived from all patients’ responses at 3 periods: (1) time of 
enrollment (initiation of placebo lead-in); (2) randomization to drug or placebo 
(week 2); and (3) termination from protocol. 
Two null hypotheses were tested: (a) there were no significant differences in pain 
measures of both treatment groups over time; and (b) there were no significant 
differences in pain measures between drug and placebo groups. 
Sample size calculations were determined based on a one-sided t test of the 
differences in pain scores between groups at entry into and termination from the 
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protocol [8]. Using (Y = 0.05, p = 0.20, and a sample size of 9 for each group, a 30% 
difference in pain scores between groups could be detected. 
Frequency distributions were determined for side effects and for global assess- 
ments of efficacy. Significant differences in these frequencies were evaluated using 
the normal approximation of the binomial distribution to obtain confidence inter- 
vals. 
Nineteen subjects participated in the study protocol. One patient failed to return 
for randomization to active drug or placebo. Characteristics of the patient sample 
are noted in Table I. The only statistically significant difference between the drug 
and placebo groups was the allocation of more sensory incomplete SC1 patients to 
the drug group (P < 0.05). There were no significant baseline differences between 
groups for PRI, NWC, PPI, SPI-day, SPI-week and PAD (Table II). 
Eight patients of the nine in the placebo group returned for all clinic visits 
following randomization (Table III). All patients in the drug group returned for at 
least one clinic visit following randomization. Compared to the placebo group, a 
significantly smaller number of patients randomized to active drug completed the 
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a Denotes a significant difference between groups at P c 0.05. Xk 2 S.E.M. 
TABLE II 








’ All values are given as F :t 2 S.E.kf 
TABLE III 
PATIENT COMPLIANCE WITH PROTOCOL 
Group Baseline Week 2 Week 4 Week 6 Week 8 (’ 
Drug 9 9 9 8 4 
Placebo 9 9 8 8 x 
-_ - I_~__ 
I’ Denotes a significant difference between groups at P c 0.01. 
TABLE IV 
SIDE EFFECTS 













2 0 2 
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2 0 
1 0 0 
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0 0 
,’ Denotes a stgnificant difference between groups at P ( 0.05 
TABLE V 
GLOBAL ASSESSMENT OF EFFICACY 
Assessment of efficacy Trazodone Placebo P 
Physician Yes 5 2 N.S. 
No 4 I N.S. 
Patients Yes 4 i N.S. 
No 5 6 N.S. 
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TABLE VI 




















All values given as X f 2 S.E.M. 
Trazodone Placebo 
33.0* 5.5 34.7 * 4.4 
33.2 + 6.9 31.2 k 6.4 
33.5 f 2.4 32.1 + 3.5 
13.2k1.9 13.951.5 
12.0+1.7 12.3f1.5 
14.Oil.O 13.2* 1.5 
2.1 kO.3 2.4 i 0.3 
2.9 + 0.6 2.1 f 0.3 
2.6 f 0.2 1.7*0.2 
57.9kll.l 55.7 f 10.4 
58.2 k 9.4 56.6 i 8.7 
61.7k6.8 63.45 8.4 
69.7 i 8.7 65.6 f 9.6 
63.8 f 7.0 62.6 k 8.8 
73.9 * 4.7 68.3 + 6.9 
56.9 f 4.6 59.0 &- 4.9 
55.1 k 4.6 55.8 k 4.4 
67.2 i 3.8 53.0f3.2 
tion at the end of the full &week protocol, a small number elected to continue for 
up to 3 months. There was a statistically significant difference in reported side 
effects between the drug and placebo groups (Table Iv). The most common 
complaints among patients on active drug were (in descending order): drowsiness, 
dry mouth, dizziness, increased spasticity and urinary retention. 
A global assessment of efficacy was completed by a physician and the patient at 
the termination clinic visit (Table V). Review of results obtained from the physician 
assessments indicated that 5 of 9 patients randomized to trazodone and 2 of 9 
patients randomized to placebo had improvement of their pain syndrome, a dif- 
ference which was not statistically significant. Review of the patient global assess- 
ments suggested that four of the patients on active drug and three of the patients 
receiving placebo reported significant improvement in pain symptoms. None of 
these subjective observations was reflected in the analysis of the pain measures, 
which showed no significant changes over time from baseline recordings (Table VI). 
Consequently, the two null hypotheses were accepted at P > 0.05: there were no 
significant differences in the pain measures over time and there were no significant 
differences in pain measures between drug and placebo groups. 
Discussion 
In the past decade, animal studies have demonstrated that an increase in the 
cerebral concentration of serotonin enhances analgesia [1,24,26], an effect which is 
antagonized by agents which inhibit serotonin synthesis and transmission [1,38]. 
1% 
These findings suggested that antidepressant rnedlcatiom which ~+~ti\;ell block 
brain serotonin reuptake may be associated with superior analgesic effect compared 
to that induced by such non-selective agent:, as amitriptyline. dnxepin and imipra- 
mine. Trazodone hydrochloride. a new antidepressant medication. ii it potent 
presynaptic serotonin reuptake blocker uith few ~~lltich(~linergic and car~i~(~v~~scular 
side effects [6,13,19.33,35]. Because of this high selectivity for aerot<lnin rcrtptakc 
inhibition and low toxicity. it was expected that trazodone hydrochloride would 
prove to be a rational choice for pharmacologic therapy of the dyxesthetic pain 
syndrome (DPS) following traumatic SCI. 
Disabling denervation dysesthesias occur in a significant number of patients with 
traumatic myelopathy [5.X.1 1,301. This DPS is characterized by diffuse burning. 
stinging and tingling sensations distal to the level of spinal injury. DPS can 
c~~rnpr~~Inise fu~lcti(~nal abilities and inhibit participati~~n in r~h~~bilitati~~l~ programs. 
The utility of tricyclic antidepressant (TCAD, medications in the treatment of 
chronic pain syndromes has been extensively investigated [3,9,14.16~-1 X.20 22,25.39]. 
Amitriptyline is efficacious in the prophylaxis of migraine [8], and in the treatment 
of post-herpetic neuralgia [39] and tension headache [22]. Imipramine has been 
shown to relieve dysesthesias resultin, 0 from painful diabetic neuropathy [ZO]. 
Two previous investigators utilized TCAD medications in the treatment of DPS 
associated with spinal cord injury with equivocal results. Using an open design. 
Heilporn [18] studied 11 inpatients with dysasthetic pain. The patients received a 
combination of 150 tng of melitracin and 1 mg of flupenthixol daily. Several 
patients received transcutaneous nerve stimulation as an adjunct to therapy. Three 
patients reported lasting relief and five had some improvement. There was no 
description of follow-up. In another published report, Maury [25] recommended the 
use of TCAD and neuroleptic medications for the treatment of radicular and 
dysesthetic pain following traumatic SC?, but provided no rationale and reported no 
data with regard to efficacy. The present study used a randomized, double-blind, 
placebo-controlled design to determine the efficacy of trazodone ~~ydrocllloride for 
the treatment of this syndrome. 
Comparison of demographic data, neurological status and pretreatment pain 
rating values revealed no significant differences between drug and placebo groups 
other than a larger number of patients with incomplete sensory myelopathy. This 
was not expected to bias the results of treatment in this group. since there was no 
significant difference in the baseline assessments for each group in this study. 
Evaluation of changes in the measures of pain quality and intensity was performed 
at 3 points: (1) enrollment: (2) randomization; and (3) exit interview. Differences in 
pain measures between points 1 and 2 were examined in an effort to determine the 
effect of placebo upon pain measures (Table VI). Differences between pain scales at 
points 2 and 3 were used to evaluate the effect of drug administration (Table VI). 
Separate analyses were conducted to determine the extent to which changes in pain 
ratings resulted from drug effect. Because duration of participation varied. the exit 
interview was chosen as the time for final outcome deter~nation. It was assumed 
that patients required at least a 2-week triai of trazodone hydrochloride to perceive 
any therapeutic effect, and that premature termination wx the result of either 
intolerable side effects or lack of therapeutic efficacy. 
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No significant changes were noted in reported pain measures during the course of 
the treatment protocol between patients allocated to active drug and those allocated 
to placebo. However, significantly more patients randomized to trazodone hydro- 
chloride complained of side effects and terminated participation in the study 
prematurely (1 patient terminated at week 4, and 3 others terminated at week 6). It 
is possible that a higher maintenance dose of trazodone hydrochloride might have 
proven efficacious in the treatment of this pain syndrome. However, the dosage used 
was equipotent to that of other TCAD medications used for the treatment of pain 
syndromes [9,10,16,17,21,22,39]. Monitoring of serum drug levels might have yielded 
information concerning dose-response relationships between study drug concentra- 
tion, therapeutic efficacy and side effects. 
Three groups of investigators have previously examined the efficacy of serotonin 
reuptake inhibitors in the treatment of pain states and found equivocal results. 
Johansson et al. [20] randomized 40 patients with chronic organic and psychogenic 
pain to a 5-week trial of either placebo or zimelidine, a potent serotonin reuptake 
inhibitor. There was a dramatic change in visual analog scale (VAS) pain ratings for 
patients allocated to the drug group compared to those of the placebo group 
following treatment. However, the VAS pain ratings of the placebo group before 
and after treatment were not significantly different from the VAS values of the drug 
group at the end of the trial. The lack of comparability between treatment groups 
may have resulted in regression to the mean of the VAS values for the zimelidine 
group. In another study, Gourlay et al. [14] studied 19 patients in a double-blind, 
placebo-controlled, cross-over study of 300 mg of zimelidine daily for 6 weeks. 
There were no significant differences in objective pain measures between active drug 
and placebo. Likewise, Andersen et al. [3] reported a double-blind, cross-over study 
of 26 patients with chronic pain utilizing citalopram (a serotonin reuptake blocker) 
and flupenthixol (a potent neuroleptic medication), in which no differences in VAS 
pain scores between the drug and placebo groups were noted. 
This investigation represents the first systematic trial of an antidepressant 
medication for the treatment of function-limiting dysesthetic pain following trau- 
matic myelopathy. Despite animal models demonstrating the importance of the 
neurotransmitter serotonin in central pain control mechanisms [9,22,38,39], results 
of this investigation support the findings of previous authors [3,14,20] that antide- 
pressant medications which selectively inhibit presynaptic reuptake of serotonin 
may not be effective in the control of certain pain syndromes. Although these results 
do not preclude the possibility of employing these agents for the treatment of other 
pain syndromes or at higher doses than previously studied, there is no evidence at 
this time to support the use of trazodone hydrochloride for the management of DPS 
following SCI. 
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